N-[(2S,5S)-5-[(2S,5S)-3-acetamido-5-[(2S,5R)-3,5-dihydroxy-4-[(2S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)-2-methyloxan-3-yl]acetamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[(2S,5S)-5-[(2S,5S)-3-acetamido-5-[(2S,5R)-3,5-dihydroxy-4-[(2S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)-2-methyloxan-3-yl]acetamide
• 化学式: C₃₅H₆₀N₂O₂₅
• 分子量: 908.8
• InChiKey: IIQYNFQCNRIEQO-CYJQVKIKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -9.7
• 重原子数：
  62
• 可旋转键数：
  15
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  425
• 氢给体数：
  16
• 氢受体数：
  25

文献信息

• GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：Glytech, Inc.

  公开号：EP2762489A1

  公开（公告）日：2014-08-06

  The object of the present invention is to provide a glycosylated polypeptide having uniform sugar chain structure which has interferon β activity. It was found that a glycosylated polypeptide having uniform sugar chain structure as well as having interferon β activity can be prepared by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking the glycosylated peptide fragment and the at least two peptide fragments.

  本发明的目的是提供一种具有均匀糖链结构、具有干扰素β活性的糖基化多肽。研究发现，具有均匀糖链结构并具有干扰素 β 活性的糖基化多肽可通过以下方法制备：合成糖基化多肽片段和至少两个多肽片段的步骤，以及连接糖基化多肽片段和至少两个多肽片段的步骤。
• Glycosylated polypeptide and pharmaceutical composition containing same
  申请人：GLYTECH, INC.

  公开号：US10358470B2

  公开（公告）日：2019-07-23

  The object of the present invention is to provide a glycosylated polypeptide having uniform sugar chain structure which has interferon β activity. It was found that a glycosylated polypeptide having uniform sugar chain structure as well as having interferon β activity can be prepared by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking the glycosylated peptide fragment and the at least two peptide fragments.

  本发明的目的是提供一种具有均匀糖链结构、具有干扰素β活性的糖基化多肽。研究发现，具有均匀糖链结构并具有干扰素 β 活性的糖基化多肽可通过以下方法制备：合成糖基化多肽片段和至少两个多肽片段的步骤，以及连接糖基化多肽片段和至少两个多肽片段的步骤。
• HEMOSTATIC PHARMACEUTICAL COMPOSITION
  申请人：OTSUKA CHEMICAL CO., LTD.

  公开号：US20170119844A1

  公开（公告）日：2017-05-04

  The object of the present invention is to provide a hemostatic pharmaceutical composition that has higher usability compared to a hemostatic agent employing conventional biogels and may form a transparent and homogeneous hydrogel in a broad pH. The present invention provides a hemostatic pharmaceutical composition comprising a sugar chain-polypeptide complex characterized in that said polypeptide in said sugar chain-polypeptide complex is a polypeptide comprising an amino acid sequence in which polar and nonpolar amino acid residues are alternately arranged, and one or more sugar chains are bound to said polypeptide.
• IL-2 VARIANT
  申请人：Kyowa Kirin Co., Ltd.

  公开号：US20210060169A1

  公开（公告）日：2021-03-04

  An object of the present invention is to provide a novel IL-2 variant which has improved selectivity for IL-2R αβγ and selectively activates Tregs. The present invention relates to an IL-2 variant, a method for producing the IL-2 variant, a composition and a therapeutic agent for an immune disease, comprising the IL-2 variant, a method for increasing selectivity of IL-2 for IL-2Rαβγ, a method for improving an affinity of IL-2 for an IL-2Rα subunit, a method of reducing an affinity of IL-2 for at least one of an IL-2Rβ subunit and an IL-2Rγ subunit, and a method for selectively activating regulatory T cells.
• US9708413B2
  申请人：——

  公开号：US9708413B2

  公开（公告）日：2017-07-18